title: Does cisplatin chemotherapy decrease the MDP uptake of normal bone? An experimental study.
abstract: OBJECTIVE
  Bone scan is the accepted initial imaging modality for skeletal metastases. Cisplatin is a cell-cycle nonspecific antineoplastic agent used in some chemotherapy regimens. Knowing that platinum reacts with phosphate compounds such as methylenediphosphonic acid (MDP), decreases bone resorption and new bone formation, it can be proposed that cisplatin chemotherapy may decrease Tc-99m MDP bone uptake. We aimed to demonstrate, if present, the decrease in bone uptake and to determine the duration of this effect.
  
  
  METHODS
  Thirty male Wistar rats were randomized into five groups, namely, placebo group (G1) and cisplatin groups (G2, G3, G4, G5). Pre-therapy bone scintigraphies were obtained in all the groups. Cisplatin chemotherapy was given as infusion. Post-therapy bone scintigraphies were obtained 10 min, 1 h, 24 h, and 72 h after chemotherapy in groups G2-G5, respectively. A placebo bone scintigraphy was obtained 10 min after infusion of serum physiologic in G1. Plasma samples for cisplatin plasma values were obtained. The graphite furnace atomic absorption spectrophotometry technique was used for cisplatin analysis. Quantitative analysis (bone uptake ratios) was performed by drawing regions of interest on the right femur, vertebral column, and adjacent soft tissues. The injection/examination time delay and the net injected MDP doses were also noted.
  
  
  RESULTS
  There was no statistically significant difference in bone uptake values, injected MDP doses or injection/examination time delay in any group. Cisplatin plasma values were significantly different in G2, G3, G4, and G5 (P < 0.05) but not in G1.
  
  
  CONCLUSIONS
  Cisplatin chemotherapy seems to have no effect on the Tc-99m MDP uptake of normal bone.
authors.affiliation: Department of Nuclear Medicine, Dokuz Eylul University School of Medicine, Inciralti, Izmir 35340, Turkey. ozhan.ozdogan@deu.edu.tr
authors.forename: Ozhan
authors.initials: O
authors.lastname: Ozdogan
authors.forename: Turkan
authors.initials: T
authors.lastname: Ertay
authors.forename: Gulhan
authors.initials: G
authors.lastname: Arslan
authors.forename: Ali R
authors.initials: AR
authors.lastname: Sisman
authors.forename: Gamze
authors.initials: G
authors.lastname: Capa Kaya
authors.forename: Osman
authors.initials: O
authors.lastname: Yilmaz
authors.forename: Canan
authors.initials: C
authors.lastname: Coker
authors.forename: Ataman
authors.initials: A
authors.lastname: Gure
authors.forename: Hatice
authors.initials: H
authors.lastname: Durak
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001842:Bone and Bones / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism*; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D004195:Disease Models, Animal; D008297:Male; D008657:Metabolic Clearance Rate; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar; D013669:Technetium Tc 99m Medronate / Q000493:pharmacokinetics*
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D002945:Cisplatin; D013669:Technetium Tc 99m Medronate